Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. announced its financial results for the year ended December 31, 2024, revealing a slight increase in revenue by 1.81% compared to the previous year, reaching RMB 50.6 billion. However, the net profit attributable to shareholders decreased by 6.80%, and the net cash flow from operating activities saw a significant decline of 39.15%. These results may impact the company’s market positioning and stakeholder confidence, as they indicate challenges in maintaining profitability and cash flow.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, primarily focusing on the distribution and retail of pharmaceutical and healthcare products. The company is a significant player in the Chinese market, with its subsidiary, China National Medicines Corporation Ltd. (SINOPHARM CNCM LTD), listed on the Shanghai Stock Exchange.
YTD Price Performance: -8.47%
Average Trading Volume: 866
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.95B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges